Moderate Versus Ultra Hypofractionation or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment
We will investigate whether ultrahypofractionation using stereotactic ablative radiotherapy (SABR) or brachytherapy is as well-tolerated as moderately hypofractionated external beam radiotherapy (EBRT) for treating the prostate in patients with oligometastatic prostate cancer. Secondary aims include assessment of progression-free survival (PFS) and overall survival (OS) as well as cost-effectiveness. We hypothesize that ultrahypofractionation will maintain favorable toxicity profiles and quality of life while achieving comparable or better efficacy, thereby providing a convenient and cost-effective alternative to moderately hypofractionated EBRT.
• Able to provide informed consent
• European Cooperative Oncology Group performance status 0 to 2
• Medically fit for all protocol treatment and follow-up
• Histologically confirmed adenocarcinoma of the prostate
• Newly diagnosed any Tumor stage, any Nodal stage but with oligo metastases
• No prior therapy for prostate cancer apart from androgen deprivation
• Able to complete the necessary investigations prior to randomization (History and physical examination, PSA)
• Able to complete the necessary investigations prior to start of Radiotherapy (Transrectal ultrasound-guided biopsy or equivalent, CT chest, abdomen \& pelvis or MRI abdomen and pelvis, and Bone scan)
• Planned for long-term androgen deprivation therapy (greater than 9 months in duration)